Cat. No. 3066
Chemical Name: N-[1-[[(Cyanomethyl)amino]carbonyl]
Biological ActivityPotent, reversible cathepsin K inhibitor (IC50 = 0.25 nM) that displays > 4000-fold selectivity over cathepsins B, L and S. Displays reduced selectivity in cell-based assays possibly due to lysosomal accumulation. Reduces collagen breakdown and promotes bone deposition in vivo. Orally active and has intrinsic fluorescence.
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
Certificate of Analysis / Product Datasheet / Safety Data Sheet
Desmarais et al (2008) Effects of cathepsin K inhibitors basicity on in vivo off-target activities. Mol.Pharmacol. 73 147. PMID: 17940194.
Falgueyret et al (2005) Lysosomotropism of basic cathepsin K inhibitors contributes to increased cellular potencies against off-target cathepsins and reduced functional selectivity. J.Med.Chem. 48 7535. PMID: 16302795.
Palmer et al (2005) Design and synthesis of tri-ring P3 benamide-containing aminonitriles as potent, selective, orally effective inhibitors of cathepsin K. J.Med.Chem. 48 7520. PMID: 16302794.
If you know of a relevant reference for this product please let us know.
Citations are publications that use Tocris products.
Do you know of a great paper that uses L 006235 from Tocris? If so please let us know.
View Related Products by Product Action
Keywords: L 006235, supplier, potent, selective, cathepsin, k, inhibitors, inhibits, osteoporosis, fluroescent, fluorescence, L006235, Tocris Bioscience, Cathepsin Inhibitor products
Find multiple products by catalog number
New Products in this Area
Potent 20S proteasome inhibitorDiprotin A
Dipeptidyl peptidase IV (DPP-IV) inhibitorAcein
High affinity angiotensin-converting enzyme (ACE) ligandTMI 1
Adam 17 (TACE) and MMP inhibitor; orally bioavailable
Follow @Tocris on Twitter
Tocris is now actively tweeting. For regular updates on news, events and special offers, follow @Tocris on Twitter.